About Dr. Hou Yingyong
Dr. Hou Yingyong (侯英勇) is a Professor, Doctoral Supervisor, and one of China's foremost pathologists, based at the Department of Pathology, Changhai Hospital, Naval Medical University (Second Military Medical University). With deep expertise in surgical pathology, gastrointestinal and hepatobiliary pathology, and molecular diagnostics, Dr. Hou is recognized as a leading authority on the pathological diagnosis of complex tumors — particularly gastrointestinal stromal tumors (GISTs), colorectal cancer, gastric cancer, hepatocellular carcinoma, and pancreatic tumors — and on the integration of molecular pathology and next-generation sequencing (NGS) into precision oncology decision-making.
Dr. Hou's particular national and international recognition in the field of gastrointestinal stromal tumor (GIST) pathology reflects a career-long commitment to understanding the molecular biology of this complex tumor type and translating that understanding into better diagnostic and therapeutic outcomes for patients. GISTs are the most common mesenchymal tumors of the gastrointestinal tract, driven in the majority of cases by activating mutations in the KIT or PDGFRA genes that are targetable by imatinib and other tyrosine kinase inhibitors. Accurate pathological diagnosis — including precise mutation genotyping — is essential for optimal treatment selection, and Dr. Hou's expertise in GIST pathology and molecular characterization makes him one of China's most sought-after consultants for this tumor type. His contributions to GIST pathology research, including studies on mutation spectrum, risk stratification, and resistance mechanisms, have been published in leading international journals and have shaped GIST management guidelines in China.
For international patients with GISTs, other gastrointestinal tumors, or diagnostically challenging pathological findings who are seeking expert second opinion or comprehensive molecular profiling, Dr. Hou and Changhai Hospital's Department of Pathology offer a level of diagnostic precision and molecular characterization that is available at only a small number of centers in China.
Hospital Affiliation: Department of Pathology, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of Pathology is a high-volume, technologically advanced diagnostic laboratory serving one of Shanghai's busiest tertiary referral hospitals, processing thousands of surgical specimens, biopsies, and cytology samples annually across all major organ systems and tumor types. The department's molecular pathology laboratory is equipped with the full range of contemporary diagnostic platforms: next-generation sequencing (NGS) for comprehensive tumor genomic profiling, fluorescence in situ hybridization (FISH) for gene amplification and fusion detection, immunohistochemistry (IHC) for protein expression and predictive biomarker assessment, PCR-based mutation detection, and RNA sequencing for fusion gene identification. The department has particular strength in gastrointestinal pathology — reflecting the high volume of gastrointestinal surgical and endoscopic specimens processed from Changhai Hospital's active gastroenterology, colorectal surgery, and hepatobiliary surgery programs — and maintains a dedicated GIST molecular pathology service that is one of the most active in China.
Clinical Specialties: What Dr. Hou Yingyong Provides
- Gastrointestinal stromal tumor (GIST) pathology and molecular characterization — histopathological diagnosis and risk stratification of GISTs using the modified NIH consensus criteria and AFIP criteria; comprehensive KIT (exons 9, 11, 13, 17) and PDGFRA (exons 12, 14, 18) mutation genotyping by Sanger sequencing and NGS; identification of PDGFRA D842V mutation and other imatinib-resistant mutations with implications for treatment selection (avapritinib); detection of KIT/PDGFRA wild-type GISTs and reflex testing for SDH deficiency, NF1, and BRAF mutations; assessment of secondary resistance mutations in imatinib-resistant GISTs; expert second opinion on GIST diagnosis and risk stratification for patients treated elsewhere
- Colorectal cancer pathology and molecular profiling — comprehensive histopathological assessment of colorectal cancer resection specimens including tumor grade, T and N stage, resection margin status, lymphovascular and perineural invasion, and tumor budding; MMR protein IHC and MSI testing for Lynch syndrome screening and immunotherapy eligibility; KRAS, NRAS, and BRAF mutation analysis for anti-EGFR therapy selection; HER2 amplification assessment by IHC and FISH; comprehensive NGS tumor profiling for TMB and additional actionable alterations
- Gastric cancer pathology — histopathological diagnosis and Lauren classification of gastric adenocarcinoma; HER2 status assessment by IHC and FISH for trastuzumab eligibility; PD-L1 expression by IHC (CPS scoring) for immunotherapy eligibility; EBV in situ hybridization; MMR/MSI testing; comprehensive molecular profiling for FGFR2, MET, and other actionable alterations in gastric cancer
- Hepatobiliary and pancreatic pathology — histopathological diagnosis of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined HCC-CCA, and liver metastases; molecular profiling of cholangiocarcinoma for FGFR2 fusions, IDH1/2 mutations, BRAF V600E, and other actionable alterations; pancreatic ductal adenocarcinoma diagnosis and KRAS/SMAD4/TP53 profiling; assessment of pancreatic cyst pathology including IPMN and MCN
- Expert second opinion in surgical pathology — comprehensive re-review of prior pathology slides, tissue blocks, and molecular testing results for patients with diagnostically challenging cases, rare tumors, or tumors of uncertain histogenesis; updated IHC panel and molecular analysis where indicated; written English-language second opinion pathology reports available through CMCS
- Comprehensive tumor molecular profiling (NGS) — large-panel NGS of tumor tissue for identification of actionable driver mutations, TMB, MSI status, copy number alterations, and structural variants including fusion genes; comprehensive genomic profiling reports with clinical annotation and treatment implications for oncologists and patients
- Predictive biomarker assessment — PD-L1 expression by IHC (multiple validated antibody clones and scoring systems); HER2 status by IHC and FISH for breast, gastric, colorectal, and other HER2-driven tumors; ALK, ROS1, RET, MET, and NTRK status by IHC and/or FISH; EGFR mutation analysis; BRCA1/2 status; MMR protein expression and MSI status
Why International Patients Choose Dr. Hou Yingyong and Changhai Hospital
International patients seek pathological consultation and molecular profiling services from Dr. Hou Yingyong for reasons that reflect both his unique expertise in GIST pathology and the comprehensive molecular diagnostics capabilities available at Changhai Hospital's Department of Pathology.
For patients with GISTs — whether newly diagnosed or with disease that has progressed on imatinib — Dr. Hou's expertise in GIST molecular characterization provides the precise mutation genotyping that is essential for optimal treatment selection. The identification of a PDGFRA D842V mutation — which confers primary resistance to imatinib and sunitinib but sensitivity to avapritinib — or of a secondary KIT resistance mutation in an imatinib-resistant GIST can fundamentally change the treatment approach and open access to therapies that would not otherwise be considered. For patients who have received a GIST diagnosis elsewhere and are uncertain about their mutation status or treatment options, a second opinion consultation with Dr. Hou frequently provides the molecular clarity needed to optimize their treatment plan.
For patients with colorectal, gastric, hepatobiliary, or pancreatic tumors, the comprehensive molecular profiling available at Changhai Hospital — including large-panel NGS, comprehensive fusion gene detection, and the full range of predictive biomarker assessments — frequently identifies actionable alterations not captured by the limited molecular testing performed at the patient's home institution, opening access to targeted therapies or clinical trials not previously considered. The cost of comprehensive molecular profiling at Changhai Hospital is substantially below that of equivalent testing in Western healthcare systems.
What to Expect at Your Consultation
Pathological consultations and molecular profiling services arranged through CMCS at Changhai Hospital's Department of Pathology begin with a review of all prior pathology reports, IHC results, and molecular testing results, as well as the patient's oncological history and current clinical status. For patients seeking expert second opinion, CMCS will coordinate the transfer of pathology slides, tissue blocks, or digitized whole-slide images to Changhai Hospital for review. Dr. Hou's team will provide a comprehensive pathological assessment including histological diagnosis, IHC panel results, and molecular profiling findings, with detailed clinical annotation of the treatment implications. A written English-language pathology report is provided after every consultation, and CMCS will facilitate direct communication between Dr. Hou's team and the patient's home oncologist for integration of the findings into the overall treatment plan.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking pathological consultation and molecular profiling with Dr. Hou Yingyong at Changhai Hospital. Our services include priority scheduling, coordination of pathology slide and tissue block transfer, certified translation of prior pathology reports, coordination of fresh biopsy procedures where required, on-site interpretation, and written English-language reporting of all pathological and molecular findings. CMCS will also facilitate direct communication between Dr. Hou's team and the patient's home oncologist to ensure seamless integration of the Changhai Hospital assessment into the patient's overall care plan.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 commenti